Michael Anyadiegwu

CMC Technology Lead, CEPI

Title: The need for manufacturability speed

Bio:

Michael is CMC Technology Lead  - Innovations within Manufacturing and Supply Chain Division at the Coalition for Epidemic Preparedness Innovations (CEPI). Michael is the lead for a CEPI call for proposals on ‘Innovations for vaccine manufacturability focused on speed’ with the aim of targeting innovative technologies that will accelerate vaccine manufacture, in response to a disease outbreak with epidemic or pandemic potential.

Michael is a Chartered Manager and Post-doctoral scientist with over 23 years’ experience of protein purification, bioprocess development and scale-up for the clinical manufacture of novel therapeutic products. Michael’s expertise include the manufacture of  Active Pharmaceutical Ingredients (APIs) such as microbially expressed domain antibodies, mammalian cell culture expressed therapeutics (including antibodies, attenuated adenoviruses, exosomes), and ribonucleic acid (RNA) products produced from a deoxyribonucleic acid (DNA) plasmid template. RNA vaccine development work includes the onboarding of RNA manufacturing technology into UK during the COVID-19 pandemic.

Michael has undertaken several roles in Industry, holds PhD and MSc degrees in Food Science and a BSc (Honours) degree in Biomedical Sciences. Michael also led a three-year collaborative project that won the Institute of Chemical Engineers Global Award for Biotechnology in 2019.